Nektar Therapeutics (NKTR.OQ)
NKTR.OQ on NASDAQ Stock Exchange Global Select Market
41.69USD
15 Feb 2019
41.69USD
15 Feb 2019
Change (% chg)
$-0.00 (-0.00%)
$-0.00 (-0.00%)
Prev Close
$41.69
$41.69
Open
$43.15
$43.15
Day's High
$43.28
$43.28
Day's Low
$40.05
$40.05
Volume
876,591
876,591
Avg. Vol
780,539
780,539
52-wk High
$111.36
$111.36
52-wk Low
$29.26
$29.26
About
Nektar Therapeutics is a biopharmaceutical company that discovers and develops medicines in areas of high unmet medical need. The Company's research and development pipeline of new investigational drugs includes treatments for cancer, auto-immune disease and chronic pain. It leverages its chemistry platform to discover and... (more)
Overall
| Beta: | 1.38 |
| Market Cap(Mil.): | $3,878.49 |
| Shares Outstanding(Mil.): | 156.33 |
| Dividend: | -- |
| Yield (%): | -- |
Financials
| NKTR.OQ | Industry | Sector | |
|---|---|---|---|
| P/E (TTM): | -- | 69.44 | 33.70 |
| EPS (TTM): | -1.40 | -- | -- |
| ROI: | -53.15 | 8.92 | 14.45 |
| ROE: | -- | 10.08 | 15.96 |
Nektar, Bristol combo drug shows signs of tumor reduction in bladder cancer patients
Nektar Therapeutics said on Friday some patients with advanced bladder cancer treated with a combination of its experimental treatment and Bristol-Myers Squibb Co's immunotherapy, Opdivo, showed signs of tumor reduction in an early-stage study.
Nektar, Bristol combo drug shows signs of tumor reduction in bladder cancer patients
Feb 15 Nektar Therapeutics said on Friday some patients with advanced bladder cancer treated with a combination of its experimental treatment and Bristol-Myers Squibb Co's immunotherapy, Opdivo, showed signs of tumor reduction in an early-stage study.
Estimates